Ind-Swift Laboratories Limited concluded its 31st Annual General Meeting on September 30, 2026, with all four proposed resolutions passing with the requisite majority. The meeting was conducted via video conference and other audio-visual means.

The shareholders approved the adoption of the audited financial statements for FY26. They also ratified the re-appointment of Navrattan Munjal as Chairman and Whole-Time Director, who retired by rotation. Additionally, the remuneration for cost auditors for FY27 was ratified.

A special resolution was passed to appoint Amit Mathur as an independent director. The voting results indicate strong shareholder support across all agenda items, with minimal dissent recorded in specific categories.

Voting results overview

The total number of shares voted upon was 41,398,203, representing 47.61% of the total outstanding shares of 86,961,558. The table below summarizes the voting outcome for each resolution:

Key observations from voting data

The re-appointment of Navrattan Munjal witnessed the highest number of dissenting votes among all resolutions, with 60,111 votes cast against it. This contrasts sharply with the other three resolutions, which received only 546 dissenting votes each. Public institutions voted against Munjal's re-appointment in significant numbers (59,565 votes), while promoter group support remained unanimous at 100% for this resolution as well.

Meeting details

The AGM commenced at 3:05 pm and concluded at 3:29 pm. Voting rights were reckoned based on holdings as of the cut-off date, September 23, 2026. Remote e-voting was facilitated by Central Depository Services (India) Limited. The scrutinizer's report confirmed that the voting process was conducted fairly and transparently.

Promoter group entity Essix Biosciences Limited acquired 70,00,000 fully convertible warrants (FCWs) in Ind-Swift Laboratories through a preferential issue on September 17, 2026. The transaction strengthens the promoter group’s consolidated diluted stake to 47.18%.

The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Essix Biosciences, acting on behalf of the promoter and promoter group, purchased the warrants for cash. Each warrant is convertible into one equity share with a face value of ₹10.

Holding Structure Changes

Before this transaction, Essix Biosciences held 3,28,82,521 shares, representing 37.92% of the total voting capital. Persons Acting in Concert (PACs), comprising family members and associates including Gopal Munjal and Himanshu Jain, held 44,51,757 shares (5.13%). The combined pre-acquisition holding stood at 43.06%.

Following the allotment of the FCWs, the total diluted share capital of Ind-Swift Laboratories increased to 9,39,61,558 equity shares. The post-acquisition structure reflects the following positions:

Note: Essix Biosciences' diluted percentage combines its direct shareholding (35.00%) and the warrant conversion potential (7.45%).

What the Numbers Show

The acquisition highlights a strategic shift towards dilutive financing for the promoter group. While the absolute number of equity shares held by Essix Biosciences remained unchanged at 3,28,82,521, its effective control expanded via the addition of 70,00,000 convertible instruments. This increased the total instrument count held by the acquirer to 4,43,34,278, pushing the consolidated diluted stake from 43.06% to 47.18%. The use of FCWs allows the promoters to increase their voting power exposure without immediate cash outlay for full equity shares, though it introduces future dilution pressure upon conversion.